• Health & Medicine

Immunotherapy for triple negative breast cancer approved for NHS in England 

Atezolizumab used in combination with nab-paclitaxel is the first immunotherapy available for triple negative breast cancer. Atezolizumab used in combination with nab-paclitaxel is the first immunotherapy available for triple negative breast cancer.

26 May 2020

• Health & Medicine

New breed of personalised cancer medicine approved in England. What does it mean for patients?

A new breed of targeted cancer drug has been approved for NHS use in England. But drugs like larotrectinib also pose unique and complex challenges for the NHS, which have been exacerbated by the COVID-19 pandemic. A new breed of targeted cancer drug has been approved for NHS use in England. But drugs like larotrectinib also pose unique and complex challenges for the NHS, which have been exacerbated by the COVID-19 pandemic.

21 April 2020

• Health & Medicine
• Policy & Insight

How coronavirus is impacting cancer services in the UK

Cancer services have been severely disrupted across the UK, from screening to treatment and care. Cancer services have been severely disrupted across the UK, from screening to treatment and care.

21 April 2020

• Health & Medicine

Three new treatment options approved for NHS use in Scotland

The Scottish Medicines Consortium (SMC) has accepted 3 new cancer treatments for NHS use in Scotland The Scottish Medicines Consortium (SMC) has accepted 3 new cancer treatments for NHS use in Scotland

26 March 2020

• Health & Medicine

Non-Hodgkin lymphoma treatment gets an initial ‘no’ for NHS use in England

A new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma has not been recommended for NHS use in England.  A new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma has not been recommended for NHS use in England. 

11 March 2020

• Health & Medicine

‘Chemotherapy-free’ treatment for lymphoma made available for NHS use in England

New ‘chemotherapy-free’ treatment for follicular lymphoma approved for NHS use in England. New ‘chemotherapy-free’ treatment for follicular lymphoma approved for NHS use in England.

28 February 2020

• Health & Medicine
• Policy & Insight

Opinion: ‘Widening health inequalities in England should be a wake-up call for the Government’

Life expectancy has failed to increase for a decade across England for the first time in 100 years. And cuts to stop smoking services are part of the problem. Life expectancy has failed to increase for a decade across England for the first time in 100 years. And cuts to stop smoking services are part of the problem.

25 February 2020

• Health & Medicine

England off track to meet government's 2030 smoke-free target

England will fail to be smoke-free by 2030 if current smoking trends continue, according to a report released today from Cancer Research UK. England will fail to be smoke-free by 2030 if current smoking trends continue, according to a report released today from Cancer Research UK.

25 February 2020

• Health & Medicine

Kidney cancer drug gets initial ‘no’ for the NHS in England

A new kidney cancer drug combination of pembrolizumab with axitinib gets an initial no for the NHS in England A new kidney cancer drug combination of pembrolizumab with axitinib gets an initial no for the NHS in England

17 February 2020

• Health & Medicine

Two skin cancer treatments get the green light for NHS Scotland

An immunotherapy and a targeted cancer drug were among the latest batch of NHS approvals from the Scottish Medicines Consortium (SMC).  An immunotherapy and a targeted cancer drug were among the latest batch of NHS approvals from the Scottish Medicines Consortium (SMC). 

12 February 2020

• Health & Medicine

Targeted lung cancer treatment gets initial ‘no’ for NHS in England

Adults in England with advanced lung cancer will not have access to a new targeted cancer drug, lorlatinib (Lorviqua).  Adults in England with advanced lung cancer will not have access to a new targeted cancer drug, lorlatinib (Lorviqua). 

4 February 2020

• Health & Medicine

Leukaemia and head and neck cancer drugs not approved for NHS use in England

Leukaemia and head and neck cancer drugs have not been recommended for NHS use in England. Leukaemia and head and neck cancer drugs have not been recommended for NHS use in England.

23 January 2020